

Roberta Rolla

CURRICULUM VITAE ET STUDIORUM

PROFESSIONAL PROFILE

Roberta Rolla is Associate Professor of General Pathology and Clinical Pathology at the University of Eastern Piedmont “Amedeo Avogadro” and carries out her clinical and healthcare activities at the Clinical Biochemistry Laboratory of the AOU “Maggiore della Carità” Hospital in Novara, where she serves as Head of the Laboratory Emergency Diagnostics Unit.

She is qualified to hold the position of Full Professor in the academic field 06/A2 – General Pathology and Clinical Pathology. Her professional activity continuously integrates university teaching, hospital practice, specialist diagnostics, applied research in laboratory medicine, participation in national and international scientific societies, and the organization of educational and scientific events of national relevance.

Her main area of interest is **Laboratory Medicine** as a central discipline within the clinical-diagnostic process, with particular focus on clinical biochemistry, specialized coagulation, laboratory hematology, molecular diagnostics, hemoglobinopathies, integrated diagnostics, and the application of digital technologies, big data, artificial intelligence, and machine learning to laboratory medicine.

EDUCATION

She obtained a Master's Degree in Biological Sciences from the University of Pavia, graduating with honors (110/110 cum laude), and completed her specialization in Clinical Pathology at the University of Eastern Piedmont “Amedeo Avogadro”, also graduating with honors (110/110 cum laude).

She also completed the managerial and professional development program “**NEXT LEADERS-LAB**” at the Centre for Research and Advanced Education in Health Administration of the University of Milan, strengthening her managerial and organizational skills applied to healthcare and laboratory settings.

ACADEMIC AND TEACHING ACTIVITIES

Her teaching activity is continuously carried out at the University of Eastern Piedmont “Amedeo Avogadro” and covers different levels of undergraduate and postgraduate education.

She teaches Clinical Pathology in the Degree Programs in Medicine and Surgery, Biomedical Laboratory Techniques, and Biotechnology, within courses dedicated to Laboratory Medicine, Integrated Diagnostics, and Molecular Diagnostics. She is currently responsible for teaching activities in the following programs:

Degree Program in Medicine and Surgery

- Integrated Course: Integrated Diagnostics – Laboratory Medicine
- Module: Clinical Pathology

Degree Program in Biomedical Laboratory Techniques

- Integrated Course: Laboratory Diagnostics
- Module: Clinical Pathology

Degree Program in Biotechnology

- Integrated Course: Clinical Biotechnology
- Module: Clinical Pathology

She also teaches in several Residency Programs at the University of Eastern Piedmont, contributing to the specialist training of physicians, biologists, and other healthcare professionals. In particular, she teaches in Residency Programs in:

- Clinical Pathology and Clinical Biochemistry
- Hematology
- Endocrinology and Metabolic Diseases
- Anesthesiology, Intensive Care and Pain Medicine
- Emergency Medicine
- Pediatrics
- Otorhinolaryngology
- General Surgery
- Medical Oncology
- Hospital Pharmacy

She is actively involved in doctoral education as a member of the Faculty Board of the PhD Program in Medical Sciences and Biotechnology at the University of Eastern Piedmont. She has also gained extensive teaching experience in postgraduate master's programs, advanced training courses, and educational activities conducted in English.

Within the university system, she holds several coordination and academic leadership roles, including coordination of integrated courses, participation in Residency Program Councils, teaching committees, and university bodies dedicated to educational quality assurance.

CLINICAL, DIAGNOSTIC, AND HEALTHCARE ACTIVITIES

Her hospital activity is carried out at the Clinical Biochemistry Laboratory of the AOU “Maggiore della Carità” Hospital in Novara, a highly specialized reference center for laboratory diagnostics.

As Head of the Laboratory Emergency Diagnostics Unit, she contributes to the organization, management, and development of diagnostic pathways in clinical biochemistry, hematology, coagulation, and molecular diagnostics, with particular attention to analytical quality, appropriateness, diagnostic turnaround time, and integration between laboratory data and clinical decision-making.

Her activity is based on a model of laboratory medicine focused not only on the production of analytical results but also on their critical interpretation, clinical value enhancement, and decision support for patient care.

RESEARCH ACTIVITIES

Research activities are conducted at the Clinical Chemistry Research Laboratory of the AOU “Maggiore della Carità” Hospital in Novara, particularly within the highly specialized fields of clinical biochemistry, specialized coagulation, laboratory hematology, and molecular diagnostics.

Her research is primarily applied research in Laboratory Medicine, based on the critical evaluation of analytical data and aimed at continuously improving the processes through which laboratory data are generated, interpreted, and translated into clinical practice.

Modern laboratories generate large volumes of data every day from patients with highly heterogeneous diseases. Consequently, laboratory research represents a dynamic and constantly evolving discipline requiring methodological rigor, analytical expertise, and strong integration with clinical needs.

A major research focus concerns the diagnostic translation of innovations arising from basic research, with particular attention to their real-world applicability, clinical value, and organizational and economic impact on healthcare systems.

In recent years, her scientific activity has increasingly focused on the impact of digital technologies, big data, artificial intelligence, and machine learning in Laboratory Medicine. These tools are transforming the role of the clinical pathologist, making it increasingly integrated within the clinical-diagnostic process and enabling

contributions to complex pattern recognition, risk stratification, predictive diagnostics, and personalized medicine.

Main research areas include:

- Integrated hematology diagnostics and advanced use of complete blood count (CBC) parameters;
- Digital morphology and artificial intelligence applied to laboratory hematology;
- Hemoglobinopathies, sickle cell disease, and newborn screening;
- Specialized coagulation, hemostasis, and thrombosis;
- Molecular diagnostics and pharmacogenetics;
- Biomarkers of inflammation, immunity, and chronic diseases;
- Prescriptive appropriateness and environmental and economic sustainability in Laboratory Medicine;
- Enhancement of laboratory data within clinical-diagnostic pathways.

Her scientific approach aims to transform analytical data into clinically actionable information, contributing to more personalized, effective, efficient, and sustainable healthcare.

SCIENTIFIC SOCIETIES AND NATIONAL AND INTERNATIONAL INSTITUTIONAL ACTIVITIES

She actively participates in national and international scientific societies in the field of Laboratory Medicine. She served as a member of the Executive Board of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (**SIBioC**) for the 2022–2025 term.

Within SIBioC, she coordinates:

- The Study Group on Anemias and Hemoglobinopathies;
- The Study Group on Education and Relations with Emerging Countries;

and serves as Deputy Coordinator of the SIBioC International Relations Division for IFCC.

She is a member of the **European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)** and serves as the Italian Corresponding Member of the IFCC–ICSH Joint Working Group on the **Standardization of Hemoglobin A2**.

Since 2021, she has been the Italian Representative for **UK NEQAS for General Haematology and Transfusion** in specific external quality assessment schemes related to hemoglobinopathies, HbA2/HbF measurement, abnormal hemoglobins, and newborn sickle cell screening.

She is also actively involved in study groups and professional networks dedicated to integrated hematology diagnostics, specialized coagulation, and harmonization of laboratory diagnostic pathways.

CONFERENCES AND CONTINUING PROFESSIONAL EDUCATION

She has carried out extensive activities as scientific organizer, course director, moderator, and lecturer in national congresses, CME-accredited courses, webinars, and educational programs, particularly in the fields of Laboratory Medicine, hematology diagnostics, hemoglobinopathies, coagulation, artificial intelligence, sustainability, and diagnostic appropriateness.

She has served on scientific committees, scientific secretariats, award juries, and as moderator and speaker at SIBioC national congresses and other major scientific events.

She has organized and directed scientific meetings focused on topics such as:

- Microbiota and microbiome;
- Advanced molecular technologies for in vitro diagnostics;
- Laboratory medicine and acute coronary syndromes;
- Screening and diagnosis of hemoglobinopathies;

- Sustainable laboratory medicine;
- Big data and artificial intelligence.

In 2026, she contributed as an invited speaker to the **Biomedical & Life Sciences Collection** by Henry Stewart Talks with an internationally distributed CME-accredited lecture entitled: **“Fundamentals of Complete Blood Count Analysis”** focusing on the fundamentals of complete blood count interpretation and distributed to healthcare professionals worldwide.

ORGANIZATION OF OR PARTICIPATION AS SPEAKER IN SCIENTIFIC CONFERENCES

- Membro del comitato scientifico organizzatore del XVIII CONVEGNO INTERREGIONALE CONGIUNTO SIBIOC PIEMONTE- VALLE D’AOSTA, accreditato ECM dal titolo “NUOVE STRATEGIE PER UN LABORATORIO CLINICO A BASSO IMPATTO AMBIENTALE”- ALESSANDRIA, 10 giugno 2026. <https://biomedica.net/16442/>
- Relatore con tema “Intelligenza artificiale in Ematologia”, XVIII CONVEGNO INTERREGIONALE CONGIUNTO SIBIOC PIEMONTE- VALLE D’AOSTA, accreditato ECM dal titolo titolo “NUOVE STRATEGIE PER UN LABORATORIO CLINICO A BASSO IMPATTO AMBIENTALE”- ALESSANDRIA, 10 giugno 2026. <https://biomedica.net/16442/>
- Relatore al 15° ITALIAN UK NEQAS H&BC USERS MEETING – WEBINAR Ematologia generale & coagulazione, accreditato ECM, con tema “L’emocromo nell’era digitale: morfologia smart e Intelligenza Artificiale al servizio della diagnosi”, 21 ottobre 2025 (<https://www.flowassessment.it/wp-content/uploads/2025/12/HBC-UK-NEQAS-Users-Meeting-2025.pdf>; Slide e video: <https://www.flowassessment.it/eventi/uk-neqas-hbc-15-italian-uk-neqas-hbc-users-meeting-ematologia-generale-coagulazione/>).
- Membro della Giuria premi del 57° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - FIRENZE, 5-7 novembre 2025. <https://sibioc.congressonazionale.com/>
- Membro del Comitato scientifico del 57° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - FIRENZE, 5-7 novembre 2025. <https://sibioc.congressonazionale.com/>
- Moderatore della Sessione “Percorsi di diagnostica ematologica integrata” del 57° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - FIRENZE, 7 novembre 2025. <https://sibioc.congressonazionale.com/>
- Membro del comitato scientifico organizzatore del XVII CONVEGNO INTERREGIONALE CONGIUNTO SIBIOC PIEMONTE- VALLE D’AOSTA, accreditato ECM dal titolo “BIG DATA E INTELLIGENZA ARTIFICIALE IN MEDICINA DI LABORATORIO”- ALESSANDRIA, 12 giugno 2025. <https://biomedica.net/12691/>
- Relatore con tema “Intelligenza artificiale in Ematologia”, XVII CONVEGNO INTERREGIONALE CONGIUNTO SIBIOC PIEMONTE- VALLE D’AOSTA, accreditato ECM dal titolo “BIG DATA E INTELLIGENZA ARTIFICIALE IN MEDICINA DI LABORATORIO”- ALESSANDRIA, 12 giugno 2025. <https://biomedica.net/12691/>
- Moderatore della terza Sessione "La fase analitica in coagulazione" nell'ambito del CONVEGNO INTERREGIONALE EMOSTASI E TROMBOSI, accreditato ECM, Eventi SIBioC Provider Medicina, Milano, 13 maggio 2025. <https://biomedica.net/12185/>
- Membro della giuria premi del 56° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - BOLOGNA, 8-10 ottobre 2024. file:///Y:/Congresso_Sibioc_2024/Programma_def_2024.pdf
- Membro della segreteria scientifica del 56° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - BOLOGNA, 8-10 ottobre 2024. file:///Y:/Congresso_Sibioc_2024/Programma_def_2024.pdf
- Relatore nella Sessione accreditata ECM dal titolo Ematologia Digitalizzata e Intelligenza Artificiale, con tema “Intelligenza artificiale e cell population data nella diagnostica delle linfocitosi”. 56° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - BOLOGNA, 8-10 ottobre 2024. file:///Y:/Congresso_Sibioc_2024/Programma_def_2024.pdf
- Relatore al WORKSHOP EQA/PT UK NEQAS dal titolo “Il contributo dei Programmi EQA/PT UK NEQAS alla formazione del personale”, con tema Screening e analisi molecolare emoglobinopatie, ” 56° CONGRESSO NAZIONALE SIBioC, BOLOGNA, 8-10 ottobre 2024. file:///Y:/Congresso_Sibioc_2024/Programma_def_2024.pdf
- Relatore nell’ambito del Corso FAD UK NEQAS H&BC 2024 - Proficiency Testing in Ematologia e Coagulazione, accreditato ECM, con tema “Lo screening neonatale e la diagnosi molecolare delle emoglobinopatie: routine di laboratorio e programmi educativi/formativi UK NEQAS H.
- Relatore nell’ambito del Corso FAD UK NEQAS H&BC 2024 - Proficiency Testing in Ematologia e Coagulazione, accreditato ECM, con tema “Diagnostica di laboratorio delle piastrinopatie e piastrinopenie”.

- Relatore nell'ambito del 14° Congresso nazionale ITALIAN UK NEQAS H USERS MEETING su Ematologia & Emoglobinopatie, accreditato ECM, con tema "Diagnostica di laboratorio delle piastrinopatie e piastrinopenie", organizzato dalla Fondazione EQAS Italia Onlus, Milano, 23 novembre 2023.
- Relatore nell'ambito del Congresso nazionale accreditato ECM dal titolo "Informazione diagnostica integrata in Ematologia, con tema "Diagnostica ematologica: nuove prospettive nell'era dell'intelligenza artificiale", nell'ambito degli Eventi SIBioC Provider Medicina, Modena, 6 dicembre 2023.
- Relatore nell'ambito del 8° CONGRESSO NAZIONALE SIPMeL "Dati, algoritmi, informazioni, dalla Medicina di Laboratorio per il processo decisionale clinico", accreditato ECM, con tema "Diagnostica ematologica: nuove prospettive nell'era dell'intelligenza artificiale", Riva del Garda, 9-11 Ottobre 2023.
- Organizzatore e Direttore scientifico del Congresso nazionale accreditato ECM dal titolo " MICROBIOTA E MICROBIOMA: DAL LABORATORIO ALLA PRATICA CLINICA", nell'ambito degli Eventi SIBioC Provider Medicina, Novara, 12 ottobre 2023.
(<https://biomedia.net/6380>; <https://www.maggioreinformazione.it>;
<https://www.facebook.com/ospedalenovara>; <https://www.instagram.com/ospedalenovara>)
- Membro della segreteria scientifica del CONFERENZA STRATEGICA SIBIOC IL MANIFESTO PER IL FUTURO DEI PROFESSIONISTI DI LABORATORIO. Società Italiana di biochimica Clinica e Biologia Molecolare Clinica Roma 20-21 maggio 2023.
<https://conferenzastrategica.it>
- Moderatore della Sessione "Sviluppare un'affidabile attività di consulenza", CONFERENZA STRATEGICA SIBIOC IL MANIFESTO PER IL FUTURO DEI PROFESSIONISTI DI LABORATORIO. Società Italiana di biochimica Clinica e Biologia Molecolare Clinica Roma 20-21 maggio 2023.
<https://conferenzastrategica.it>
- Relatore nell'ambito del 13° Congresso ITALIAN UK NEQAS H USERS MEETING su Ematologia & Emoglobinopatie, accreditato ECM, con tema "Lo screening delle emoglobinopatie: report 2022 esercizi educativi UK NEQAS H", organizzato dalla Fondazione EQAS Italia Onlus, Milano, 24 novembre 2022.
- Membro della segreteria scientifica del 54° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - GENOVA, 5-7 ottobre 2022.
<https://sibioc.congressonazionale.com/2022>
- Moderatore della Sessione "Il contributo del Laboratorio di Coagulazione nel monitoraggio delle terapie antitrombotiche: interazione Clinica-Laboratorio". 54° CONGRESSO NAZIONALE SIBioC - GENOVA, 5-7 ottobre 2022.
<https://sibioc.congressonazionale.com/2022/>
- Membro della giuria premi del 54° CONGRESSO NAZIONALE SIBioC - Società Italiana di biochimica Clinica e Biologia Molecolare Clinica - GENOVA, 5-7 ottobre 2022. <https://sibioc.congressonazionale.com/2022/>
- Organizzatore e Direttore scientifico del Congresso accreditato ECM dal titolo "IL LABORATORIO "MOLECOLARE": TECNOLOGIE AVANZATE A DISPOSIZIONE DELLA DIAGNOSTICA IN VITRO", nell'ambito degli Eventi SIBioC Provider Medicina, Alessandria, 9 giugno 2022.
<https://biomedia.net/3937/>
- Organizzatore e Direttore scientifico del Congresso Webinar accreditato ECM dal titolo "Il Laboratorio Analisi nella gestione delle sindromi coronariche acute", organizzato nell'ambito degli Eventi SIBioC Provider Medicina, 01/12/2021.
- Relatore nel Congresso Webinar accreditato ECM dal titolo "Il Laboratorio Analisi nella gestione delle sindromi coronariche acute", organizzato nell'ambito degli Eventi SIBioC Provider Medicina, con tema "Le piastrine, cellule Giano Bifronte e il ruolo del laboratorio", 01/12/2021.
- Relatore nell'ambito del 12° ITALIAN UK NEQAS H USERS MEETING, Focus: Emoglobinopatie, accreditato ECM, con tema "Lo screening neonatale e la diagnosi molecolare delle emoglobinopatie: routine di laboratorio e programmi educativi/formativi UK NEQAS H", organizzato dalla Fondazione EQAS Italia Onlus, 28/10/2021.
<https://www.flowassessment.it/wp-content/uploads/2021/09/H-UK-NEQAS-MEETING-EMOGLOBINOPATIE-Programma-2021.pdf>
- Relatore con tema "Diagnostica delle emoglobinopatie nel laboratorio di base " nella Sessione "ANEMIE: dalla tecnologia al processo decisionale clinico", 52° Congresso nazionale SIBIOC. Virtual Edition, 6-8 ottobre 2020.
<https://bvent.biomedia.net/gestionale/documenti/evento/2849/programma.pdf>
- Relatore, Congresso nazionale accreditato ECM "LABORATORIO E CLINICA A CONFRONTO NELLA DIAGNOSTICA DELLE TALASSEMIE ED EMOGLOBINOPATIE", con tema "Diagnostica di laboratorio delle emoglobinopatie", organizzato presso AOU "Maggiore della carità", Novara, 27-03-2019.
<https://bvent.biomedia.net/gestionale/documenti/evento/2648/programma.pdf?815>

- Responsabile Scientifico, Congresso nazionale accreditato ECM "LABORATORIO E CLINICA A CONFRONTO NELLA DIAGNOSTICA DELLE TALASSEMIE ED EMOGLOBINOPATIE" ", organizzato presso AOU "Maggiore della carità", Novara, 27-03-2019.
<https://bvent.biomedica.net/gestionale/documenti/evento/2648/programma.pdf?815>
- Relatore con tema "The new research hematologic parameter NEUT-RI in the systemic bacterial infection " nella Sessione "Camminata tra i poster", 51° Congresso nazionale SIBIOC. Padova, 20-22 novembre 2019.
- Relatore con tema "The automation and the traceability of the analytical process in genetics: the Novara experience " nella Sessione "Camminata tra i poster", 51° Congresso nazionale SIBIOC. Padova, 20-22 novembre 2019.
- Relatore, Congresso accreditato ECM "Screening delle emoglobinopatie in neonati a rischio in un'Italia che cambia" con tema "Esperienza di Novara: presente e futuro e presentazione di alcuni casi clinici", organizzato presso AOU "Maggiore della carità", Novara, 20 giugno 2018.
<http://www.iatomed.it/conferences/screening-delle-emoglobinopatie-in-neonati-a-rischio-in-italia-che-cambia>
- Responsabile scientifico, Congresso accreditato ECM "Screening delle emoglobinopatie in neonati a rischio in un'Italia che cambia" organizzato presso AOU "Maggiore della carità", Novara, 20 giugno 2018.
<http://www.iatomed.it/conferences/screening-delle-emoglobinopatie-in-neonati-a-rischio-in-italia-che-cambia>
- Relatore con tema "Association between high-residual platelet reactivity in patients receiving dual antiplatelet therapy, Vitamin D plasma levels and Vitamin D Binding Protein rs7041 polymorphism". 49° Congresso Nazionale SIBIOC, Firenze dal 16-10-2017 al 18-10-2017.
- Relatore con tema "Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease ". 49° Congresso nazionale SIBIOC. Firenze dal 16-10-2017 al 18-10-2017.
- Relatore con tema "Lo screening e l'approfondimento diagnostico delle emoglobinopatie in una società ormai multi-etnica" nell'ambito del Convegno dal titolo "Appropriatezza negli esami di laboratorio", presso L'Ordine dei Medici di Novara dal 16-04-2016 al 16-04-2016.
- Responsabile Scientifico del Convegno ECM "Farmacogenetica e variabilità individuale nella risposta al farmaco. Aspetti clinici, diagnostici e gestionali", presso Università del Piemonte Orientale "Amedeo Avogadro", Novara dal 11-06-2010 al 11-06-2010.
- Relatore con tema "Diagnostica molecolare: la Farmacogenetica" nell'ambito del Convegno ECM "Farmacogenetica e variabilità individuale nella risposta al farmaco. Aspetti clinici, diagnostici e gestionali", presso Università del Piemonte Orientale "Amedeo Avogadro", Novara dal 11-06-2010 al 11-06-2010.
- Relatore con tema "Appropriatezza dei test genetici nelle trombofilie" nell'ambito del Corso di formazione "L'appropriatezza dei test genetici nel campo delle malattie complesse (Celiachia, Diabete tipo I, Trombofilia) e della farmacogenetica", presso l'AOU "Maggiore delle Carità", Novara dal 28-01-2009 al 28-01-2009.
- Relatore con tema "Terapia personalizzata: la Farmacogenomica" nel Convegno ECM "Avanguardie nel laboratorio di eccellenza"; AQUI TERME (AL) dal 29-09-2009 al 29-09-2009.
- Relatore con tema "La diagnostica molecolare nei percorsi clinici del sovraccarico di ferro" nell'ambito del Convegno dal titolo "Diagnostica Molecolare", presso l'AOU "Maggiore delle Carità", Novara dal 15-05-2008 al 15-05-2008.
- Relatore con tema "Presentazione metodiche di ibridazione inversa e relazione dell'attività svolta nel Settore di Diagnostica Molecolare" nell'ambito del Convegno ECM "Attualità e problematiche in tema di diagnostica molecolare", presso l'AOU "Maggiore delle Carità", Novara dal 20-02-2004 al 20-02-2004.

SCIENTIFIC OUTPUT

Her scientific activity includes an extensive publication record in national and international journals, encompassing original research articles, review papers, case reports, society documents, and articles focused on Laboratory Medicine.

The main areas of scientific interest include laboratory hematology, hemoglobinopathies, coagulation, molecular diagnostics, immunology, biomarkers, infectious diseases, COVID-19, environmental sustainability in clinical laboratories, test-ordering appropriateness, biobanking, digital morphology, and applications of artificial intelligence in diagnostics.

Her scientific output is documented by a well-established bibliometric profile, with **more than 170 indexed publications, a Scopus h-index of 26, and over 2,700 citations.**

She is the author and co-author of articles published in leading international journals in the fields of Laboratory Medicine, Hematology, Immunology, Clinical Biochemistry, Diagnostics, and Translational Research.

She has also contributed to textbooks, monographs, and educational materials, including chapters dedicated to Laboratory Medicine and hematological pathophysiology.

SCIENTIFIC PUBLICATIONS

BOOKS

1. **Author of the chapter** entitled “Physiological Changes in Hematopoiesis and Associated Disorders During Pregnancy” **in the monograph Pregnancy and Prenatal Screening** (Clinical Biochemistry, Special Supplement 1, 2022; SS1).
2. **Author of the Laboratory Medicine chapters** in the second edition of the Internal Medicine textbook *Internal Medicine: Methodology, Semiology, Pathophysiology, Clinical Practice and Medical Therapy*, edited by Prof. Ettore Bartoli, Chirone Moderno Publisher, September 29, 2024.

E-LEARNING COURSES

1. **Invited Speaker in the UK NEQAS H&BC 2024 E-Learning Course** – Proficiency Testing in Hematology and Coagulation (CME-accredited), delivering the lecture entitled “Newborn Screening and Molecular Diagnosis of Hemoglobinopathies: Laboratory Practice and UK NEQAS H Educational and Training Programs.”
2. **Invited Speaker in the UK NEQAS H&BC 2024 E-Learning Course** – Proficiency Testing in Hematology and Coagulation (CME-accredited), delivering the lecture entitled “Laboratory Diagnosis of Platelet Disorders and Thrombocytopenias.”

SELECTED INTERNATIONAL ACTIVITIES

1. **Invited CME Course – Henry Stewart Talks (International Educational Platform).** Fundamentals of Complete Blood Count Analysis. Biomedical & Life Sciences Collection, Henry Stewart Talks, 2026. Accredited Continuing Medical Education (CME) activity distributed internationally to healthcare professionals. DOI: 10.69645/FECF7074.

PEER-REVIEWED PUBLICATIONS

BIBLIOMETRIC INDICATORS

SCOPUS H-INDEX: **26**

CITATIONS: **MORE THAN 2,700**

PUBLICATIONS: **181** PEER-REVIEWED SCIENTIFIC PAPERS

2. **Rolla R.** (2026, May 28). Fundamentals of complete blood count analysis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 2, 2026, from <https://doi.org/10.69645/FECF7074>
3. Puggioni A, Nembrini S, Esposito T, Giovanniello A, Cappellano G, Raineri D, Burgener A, Scotti L, Grossini E, **Rolla R**, Cammarota G, Manfredi M, Chiocchetti A, Vaschetto R; HBO Eastern Piedmont Network Collaborators. Plasma extracellular vesicle levels in acute carbon monoxide poisoning: the Eastern Piedmont experience. *Crit Care*. 2026 Mar 2;30(1):100. doi: 10.1186/s13054-026-05896-z. PMID: 41772711; PMCID: PMC12952067.
4. Stangalini S, Sacchetti S, Tillio P, Giacomini L, Zanotti V, Puricelli C, Dianzani U, **Rolla R**. Green laboratory through test ordering appropriateness and innovation. *Clin Chem Lab Med*. 2026 Feb 3;64(5):1031-1037. doi: 10.1515/cclm-2025-1606. PMID: 41630517.

5. Cracas SV, Garro G, Venetucci J, Martorana M, Antona A, Bettio V, Rossato D, Briacca L, Viola E, Caristia S, Colombo V, Capuzzi L, Roveda C, Varalda M, **Rolla R**, Sacchetti S, Tillio PA, Faggiano F, Capello D. Update of the Novara Cohort Study (NCS): protocol evolution of a population-based longitudinal study on ageing in Northern Italy - cohort profile. *BMJ Open*. 2026 Jan 30;16(1):e109328. doi: 10.1136/bmjopen-2025-109328. PMID: 41617235; PMCID: PMC12863315.
6. Stoppa I, Provera A, Sacchetti S, Clemente N, Pantham D, Christaki F, Vecchio C, Sheferaw AN, **Rolla R**, Dianzani C, Sutti S, Dianzani U. ICOSL: more than a trigger of ICOS function. *Cell Commun Signal*. 2025 Nov 26;23(1):550. doi: 10.1186/s12964-025-02559-4. PMID: 41299676; PMCID: PMC12750674.
7. Paleari R, Vidali M, **Rolla R**, Ceriotti F, Ammirabile M, Mosca A. Blood collected on dry blood spots is fit for newborn screening of sickle cell disease (SCD) by different analytical systems. *Clin Chim Acta*. 2026 Jan 1;578:120528. doi: 10.1016/j.cca.2025.120528. Epub 2025 Aug 5. PMID: 40754198.
8. Tonello S, **Rolla R**, Tillio PA, Sainaghi PP, Colangelo D. Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology. *Pharmaceuticals (Basel)*. 2025 Jun 18;18(6):915. doi: 10.3390/ph18060915. PMID: 40573308; PMCID: PMC12195999.
9. Cracas SV, Aleni C, Garro G, Antona A, Venetucci J, Bettio V, Varalda M, Scotti L, Ferrante D, **Rolla R**, Faggiano F, Capello D. Investigating aging trajectories and determinants in Northern Italy through the Novara cohort study. *Sci Rep*. 2025 May 23;15(1):17908. doi: 10.1038/s41598-025-02947-3. PMID: 40410381; PMCID: PMC12102150.
10. Antona A, Bettio V, Venetucci J, Cracas SV, Mazzucco E, Garro G, Varalda M, Fontanarosa C, Spinelli M, Amoresano A, **Rolla R**, Capello D. Evaluating Cryopreservation Methods in Biobanking: Impacts on Biomarker Integrity and Omics Data Reliability. *Biopreserv Biobank*. 2025 Oct;23(5):439-448. doi: 10.1089/bio.2024.0141. Epub 2025 Mar 18. PMID: 40098524.
11. Sacchetti S, Bellia M, Vidali M, Zanotti V, Giacomini L, Gaidano G, Patriarca A, Dianzani U, **Rolla R**. Comparative Analysis of the Performance of Automated Digital Cell Morphology Analyzers for Leukocyte Differentiation in Hematologic Malignancies: Mindray MC-80 Versus West Medical Vision Hema. *Int J Lab Hematol*. 2025 Aug;47(4):643-650. doi: 10.1111/ijlh.14470. Epub 2025 Mar 27. PMID: 40148102.
12. Venegoni C, Raineri D, Mazzucca CB, Ghazanfar A, Cappellano G, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, Cantaluppi V, Patti G, Giordano M, Manfredi M, **Rolla R**, Sainaghi PP, Pirisi M, Bellan M, Chiocchetti A. Post-COVID-19 sequelae are associated with sustained SARS-CoV-2-specific CD4+ immune responses. *Int Immunopharmacol*. 2025 Feb 20;148:114103. doi: 10.1016/j.intimp.2025.114103. Epub 2025 Jan 27. PMID: 39874845.
13. Christaki F, Ghasemi A, Pantham D, Abouali R, Provera A, Vecchio C, Sheferaw AN, Dianzani C, Sutti S, **Rolla R**, Sacchetti S, Giacomini L, Dianzani U, Stoppa I. Role of Balanced Involvement of the ICOS/ICOSL/Osteopontin Network in Cutaneous Wound Healing. *Int J Mol Sci*. 2024 Nov 19;25(22):12390. doi: 10.3390/ijms252212390. PMID: 39596455; PMCID: PMC11594701.
14. Mosca A, Paleari R, Palazzi G, Pancaldi A, Lughetti L, Venturelli D, **Rolla R**, Pavanello E, Ceriotti F, Ammirabile M, Capri S, Piga A and Ivaldi G on behalf of the SIBioC Working Group on Diabetes and of the SIBioC-SIMMESN Working Group on Neonatal Clinical Biochemistry and Metabolic Diseases. Screening for sickle cell disease: focus on newborn investigations. *Biochimica Clinica*, 2024; DOI: 10.19186/BC_2024.032.
15. Zanotti V, Sacchetti S, Giacomini L, Dianzani U, **Rolla R**. The Critical Role of the Complete Blood Count in the Diagnosis of Candidemia: A Case Report. *J Clin Stud Med Case Rep* 2024, 11: 228 DOI: 10.24966/CSMC-8801/1000228
16. Sacchetti S, Bellia M, Zanotti V, Giacomini L, **Rolla R**. Detection of a Lymphoproliferative Disorder With Suspected Scattergram Analysis Using the Mindray BC-6800 Plus Automated Hematology Analyzer: A Case Report. *Int J Lab Hematol*. 2024 Oct 10. doi: 10.1111/ijlh.14378. Epub ahead of print. PMID: 39387116.
17. Cumitini L, Renda G, Giordano M, **Rolla R**, Shail T, Sacchetti S, Iezzi L, Giacomini L, Zanotti V, Auciello R, et al. Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation. *Journal of Clinical Medicine*. 2024; 13(9):2545. <https://doi.org/10.3390/jcm13092545>.
18. Sacchetti S, Puricelli C, Mennuni M, Zanotti V, Giacomini L, Giordano M, Dianzani U, Patti G, **Rolla R**. Research into New Molecular Mechanisms in Thrombotic Diseases Paves the Way for Innovative Therapeutic Approaches. *Int J Mol Sci*. 2024 Feb 21;25(5):2523. doi: 10.3390/ijms25052523. PMID: 38473772; PMCID: PMC10932156.
19. Sacchetti S, Vidali M, Esposito T, Zorzi S, Burgener A, Ciccarello L, Cammarota G, Zanotti V, Giacomini L, Bellan M, Pirisi M, Lopez RS, Dianzani U, Vaschetto R, **Rolla R**. The Role of New Morphological Parameters Provided by the BC 6800 Plus Analyzer in the Early Diagnosis of Sepsis. *Diagnostics (Basel)*. 2024 Feb 4;14(3):340. doi: 10.3390/diagnostics14030340. PMID: 38337856; PMCID: PMC10855753.
20. Montagnana M., **Rolla R**. Sviluppare una affidabile attività di consulenza. *Biochimica Clinica*, Vol.47 SS2 S28-35. Ottobre 2, 2023, DOI: 10.19186/BC_2023.074.

21. Del Ben F., Pisapia A., Padoan A., **Rolla R.**, Trenti T., Banfi G., Carobene A., Tomaiuolo R. Adempimenti per l'avvio di studi osservazionali retrospettivi in medicina di laboratorio. *Biochimica Clinica*, DOI: 10.19186/BC_2023.094.
22. Provera A, Ramavath NN, Gadipudi LL, Gigliotti CL, Boggio E, Vecchio C, Stoppa I, **Rolla R**, Boldorini R, Pirisi M, Smirne C, Albano E, Dianzani U, Sutti S. Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis. *Front Immunol*. 2023 Nov 22;14:1290391. doi: 10.3389/fimmu.2023.1290391. PMID: 38077334; PMCID: PMC10702974.
23. The role of infected red blood cells flag (InR) of Mindray BC 6800 plus in malaria diagnosis. Sacchetti S, Zanotti V, Giacomini L, Merlo A, **Rolla R**. *Int J Lab Hematol*. 2023 Sep 13. doi: 10.1111/ijlh.14172. Epub ahead of print. PMID: 37704264.
24. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease. Giacomini L, Puricelli C, Sacchetti S, Zanotti V, **Rolla R**. *Int J Lab Hematol*. 2023 Dec;45(6):831-832. doi: 10.1111/ijlh.14153. Epub 2023 Aug 21. PMID: 37604778.
25. Lupus anticoagulant mixing studies and normalization of results how best to proceed. Montaruli B, Bairo A, Beltrami E, Cabodi D, Muccini E, Papandrea M, **Rolla R**, Sampietro S, Valesella P, Sciascia S. *Int J Lab Hematol*. 2024 Feb;46(1):183-189. doi: 10.1111/ijlh.14187. Epub 2023 Oct 17. PMID: 37846783.
26. Role of the Microbiota in Skin Neoplasms: New Therapeutic Horizons. Savoia P, Azzimonti B, **Rolla R**, Zavattaro E. *Microorganisms*. 2023 Sep 25;11(10):2386. doi: 10.3390/microorganisms11102386. PMID: 37894044; PMCID: PMC10608979.
27. Genes and Microbiota Interaction in Monogenic Autoimmune Disorders. Costa F, Beltrami E, Mellone S, Sacchetti S, Boggio E, Gigliotti CL, Stoppa I, Dianzani U, **Rolla R**, Giordano M. *Biomedicines*. 2023 Apr 8;11(4):1127. doi: 10.3390/biomedicines11041127. PMID: 37189745; PMCID: PMC10135656.
28. Extracellular vesicles from human plasma for biomarkers discovery: Impact of anticoagulants and isolation techniques. Bettio V, Mazzucco E, Antona A, Cracas S, Varalda M, Venetucci J, Bruno S, Chiabotto G, Venegoni C, Vasile A, Chiocchetti A, Quaglia M, Camussi G, Cantaluppi V, Panella M, **Rolla R**, Manfredi M, Capello D. *PLoS One*. 2023 May 10;18(5):e0285440. doi: 10.1371/journal.pone.0285440. PMID: 37163560; PMCID: PMC10171685.
29. Decreased Gas6 and sAxl Plasma Levels Are Associated with Hair Loss in COVID-19 Survivors. Apostolo D, D'Onghia D, Tonello S, Minisini R, Baricich A, Gramaglia C, Patrucco F, Zeppegno P, Acquaviva A, Balbo PE, Castello LM, Cappellano G, Chiocchetti A, Gerevini C, Giordano M, Laaguid F, Manfredi M, Raineri D, Rigamonti C, Rolla R, Romano V, Confalonieri M, Savoia P, Zavattaro E, Pirisi M, Ruaro B, Sainaghi PP, Bellan M; No-More COVID Group. *Int J Mol Sci*. 2023 Mar 26;24(7):6257. doi: 10.3390/ijms24076257. PMID: 37047229; PMCID: PMC10094682.
30. Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation. Puricelli C, Gigliotti CL, Stoppa I, Sacchetti S, Pantham D, Scomparin A, **Rolla R**, Pizzimenti S, Dianzani U, Boggio E, Sutti S. *Pharmaceutics*. 2023 Jun 20;15(6):1772. doi: 10.3390/pharmaceutics15061772. PMID: 37376219; PMCID: PMC10301392.
31. Exploring the Effects of Probiotic Treatment on Urinary and Serum Metabolic Profiles in Healthy Individuals. Di Cesare F, Calgaro M, Ghini V, Squarzanti DF, De Prisco A, Visciglia A, Zanetta P, **Rolla R**, Savoia P, Amoroso A, Azzimonti B, Vitulo N, Tenori L, Luchinat C, Pane M. *J Proteome Res*. 2023 Dec 1;22(12):3866-3878. doi: 10.1021/acs.jproteome.3c00548. Epub 2023 Nov 16. PMID: 37970754; PMCID: PMC10696601.
32. Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis. Provera A, Ramavath NN, Gadipudi LL, Gigliotti CL, Boggio E, Vecchio C, Stoppa I, **Rolla R**, Boldorini R, Pirisi M, Smirne C, Albano E, Dianzani U, Sutti S. *Front Immunol*. 2023 Nov 22;14:1290391. doi: 10.3389/fimmu.2023.1290391. PMID: 38077334; PMCID: PMC10702974.
33. Lipoprotein associated- phospholipase A2 in STEMI vs. NSTEMI-ACS patients: a marker of cardiovascular atherosclerotic risk rather than thrombosis. Verdoia M, **Rolla R**, Gioscia R, Rognoni A, De Luca G; Novara Atherosclerosis Study Group (NAS). *J Thromb Thrombolysis*. 2023 Apr 6. doi: 10.1007/s11239-023-02801-1. Online ahead of print. PMID: 37022507
34. Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications. Boggio E, Gigliotti CL, Stoppa I, Pantham D, Sacchetti S, **Rolla R**, Grattarola M, Monge C, Pizzimenti S, Dianzani U, Dianzani C, Battaglia L. *Pharmaceutics*. 2023 Mar 14;15(3):937. doi: 10.3390/pharmaceutics15030937. PMID: 36986798 Free PMC article. Review.
35. Platelets, Protean Cells with All-Around Functions and Multifaceted Pharmacological Applications. Puricelli C, Boggio E, Gigliotti CL, Stoppa I, Sutti S, Giordano M, Dianzani U, **Rolla R**. *Int J Mol Sci*. 2023 Feb 26;24(5):4565. doi: 10.3390/ijms24054565. PMID: 36901997 Free PMC article. Review.

36. Differential Modulation of Human M1 and M2 Macrophage Activity by ICOS-Mediated ICOSL Triggering. Gigliotti CL, Dianzani C, Stoppa I, Monge C, Sutti S, Sblattero D, Puricelli C, **Rolla R**, Dianzani U, Boggio E. *Int J Mol Sci*. 2023 Feb 2;24(3):2953. doi: 10.3390/ijms24032953. PMID: 36769276 Free PMC article.
37. Circulating Peptidome Is Strongly Altered in COVID-19 Patients. Baldanzi G, Purghè B, Ragnoli B, Sainaghi PP, **Rolla R**, Chiocchetti A, Manfredi M, Malerba M. *Int J Environ Res Public Health*. 2023 Jan 14;20(2):1564. doi: 10.3390/ijerph20021564. PMID: 36674321 Free PMC article.
38. Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study. Bellan M, Apostolo D, Albè A, Crevola M, Errica N, Ratano G, Tonello S, Minisini R, D'Onghia D, Baricich A, Patrucco F, Zeppego P, Gramaglia C, Balbo PE, Cappellano G, Casella S, Chiocchetti A, Clivati E, Giordano M, Manfredi M, Patti G, Pinato DJ, Puricelli C, Raineri D, **Rolla R**, Sainaghi PP, Pirisi M; No-More COVID study group. *Front Immunol*. 2022 Dec 19;13:1038227. doi: 10.3389/fimmu.2022.1038227. eCollection 2022. PMID: 36601115 Free PMC article.
39. In Vitro Selection of Lactobacillus and Bifidobacterium Probiotic Strains for the Management of Oral Pathobiont Infections Associated to Systemic Diseases. Zanetta P, Squarzanti DF, di Coste A, **Rolla R**, Valletti PA, Garzaro M, Dell'Era V, Amoruso A, Pane M, Azzimonti B. *Int J Mol Sci*. 2022 Dec 18;23(24):16163. doi: 10.3390/ijms232416163. PMID: 36555802 Free PMC article.
40. Multicentric evaluation of the variability of digital morphology performances also respect to the reference methods by optical microscopy. Da Rin G, Seghezzi M, Padoan A, Pajola R, Bengiamo A, Di Fabio AM, Dima F, Fanelli A, Francione S, Germagnoli L, Lorubbio M, Marzoni A, Pipitone S, **Rolla R**, Bagorria Vaca MDC, Bartolini A, Bonato L, Sciacovelli L, Buoro S; Italian Working Group on Diagnostic Hematology of the Italian Society of Clinical Chemistry and Clinical Molecular Biology (WGDH-SIBioC). *Int J Lab Hematol*. 2022. doi: 10.1111/ijlh.13943. Online ahead of print. PMID: 35916349.
41. Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review. Puricelli C, Boggio E, Gigliotti CL, Stoppa I, Sutti S, **Rolla R**, Dianzani U. *Pharmaceutics*. 2022;14(9):1782. doi: 10.3390/pharmaceutics14091782. PMID: 36145531 Free PMC article. Review.
42. ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo. Stoppa I, Gigliotti CL, Clemente N, Pantham D, Dianzani C, Monge C, Puricelli C, **Rolla R**, Sutti S, Renò F, Boldorini R, Boggio E, Dianzani U. *Int J Mol Sci*. 2022;23(13):7363. doi: 10.3390/ijms23137363. PMID: 35806368 Free PMC article.
43. The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report. Puricelli C, **Rolla R**, Gigliotti L, Boggio E, Beltrami E, Dianzani U, Keller R. *Front Psychiatry*. 2022;12:755171. doi: 10.3389/fpsy.2021.755171. eCollection 2021. PMID: 35185631.
44. Barberis E, Amede E, Khoso S, Castello L, Sainaghi PP, Bellan M, Balbo PE, Patti G, Brustia D, Giordano M, Rolla R, Chiocchetti A, Romani G, Manfredi M, Vaschetto R. *Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate. Metabolites*. 2021 Dec 6;11(12):847. doi: 10.3390/metabo11120847. PMID: 34940605; PMCID: PMC8708149.
45. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment. Boggio E, Gigliotti CL, Moia R, Scotta A, Crespi I, Boggione P, De Paoli L, Deambrogi C, Garzaro M, Vidali M, Chiocchetti A, Stoppa I, **Rolla R**, Dianzani C, Monge C, Clemente N, Gaidano G, Dianzani U. *Br J Haematol*. 2022 Mar;196(6):1369-1380. doi: 10.1111/bjh.17968. Epub 2021 Dec 26. PMID: 34954822
46. Does Mediterranean Adequacy Index Correlate with Cardiovascular Events in Patients with Advanced Chronic Kidney Disease? An Exploratory Study. De Mauri A, Carrera D, Vidali M, Bagnati M, **Rolla R**, Riso S, Chiarinotti D, Torreggiani M. *Nutrients*. 2022 Apr 19;14(9):1687. doi: 10.3390/nu14091687. PMID: 35565655.
47. Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial. De Mauri A, Carrera D, Bagnati M, **Rolla R**, Vidali M, Chiarinotti D, Pane M, Amoruso A, Del Piano M. *Nutrients*. 2022 Apr 14;14(8):1637. doi: 10.3390/nu14081637. PMID: 35458199.
48. Wrong blood in tube: a SIBioC project for a persistent problem. A. Aita A. Padoan R. Guerranti M. Fiorini C. Bellini F. Tosato M. Pelloso E. Piva R. Pajola M. Lorubbio B. Cremonesi A. Bassi R. **Rolla R** G. Introcaso M. Plebani S. Buoro F. Balboni. *Biochimica Clinica* 2022; 46(1) 051-057, DOI: 10.19186/BC_2021.048.
49. SARS-CoV-2 and the new era of vaccines – Part I: Introduction to the available vaccine platforms and their mechanism of action. Puricelli C., Carnaghi B., Dianzani U., **Rolla R**. *Biochimica Clinica* 2022; 46(1) 009-015, DOI: 10.19186/BC_2021.064.
50. SARS-CoV-2 and the new era of vaccines – Part II Currently available vaccines to fight the COVID-19 pandemic and the laboratory role in the vaccination campaign. Puricelli C., Carnaghi B., Dianzani U., **Rolla R**. *Biochimica Clinica* 2022; 46(1) 016-033, DOI: 10.19186/BC_2021.065.
51. Physiological changes in hematopoiesis during pregnancy and associated pathologies. Lorubbio M., **Rolla R**., Da Rin G. *Biochimica Clinica* 2022; 46(3) S019-S030, DOI: 10.19186/BC_2022.050.

52. Compliance, Adherence and Concordance Differently Predict the Improvement of Uremic and Microbial Toxins in Chronic Kidney Disease on Low Protein Diet. De Mauri A, Carrera D, Vidali M, Bagnati M, **Rolla R**, Riso S, Torreggiani M, Chiarinotti D. *Nutrients*. 2022 Jan 23;14(3):487. doi: 10.3390/nu14030487. PMID: 35276846.
53. Relationship between vitamin D and cholesterol levels in STEMI patients undergoing primary percutaneous coronary intervention. Verdoia M, Viglione F, Boggio A, Stefani D, Panarotto N, Malabaila A, **Rolla R**, Soldà PL, Stecco A, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis*. 2022 Apr;32(4):957-964. doi: 10.1016/j.numecd.2021.11.014. Epub 2021 Dec 4. PMID: 35078678
54. Platelets: 'multiple choice' effectors in the immune response and their implication in COVID-19 thromboinflammatory process. **Rolla R**, Puricelli C, Bertoni A, Boggio E, Gigliotti CL, Chiocchetti A, Cappellano G, Dianzani U. *Int J Lab Hematol*. 2021 Mar 22. doi: 10.1111/ijlh.13516. Online ahead of print. PMID: 33749995 Review.
55. Outcomes of music therapy interventions in cancer patients-A review of the literature. Carla Gramaglia C, Gambaro E, Vecchi C, Licandro D, Raina G, Pisani C, Burgio V, Farruggio S, **Rolla R**, Deantonio L, Grossini E, Krenkli M, Zeppegno P. *Review Crit Rev Oncol Hematol* 2019 Jun;138:241-254. doi: 10.1016/j.critrevonc.2019.04.004. Epub 2019 Apr 5. PMID: 31121392 DOI: 10.1016/j.critrevonc.2019.04.004
56. Psychotherapy with Music Intervention Improves Anxiety, Depression and the Redox Status in Breast Cancer Patients Undergoing Radiotherapy: A Randomized Controlled Clinical Trial. Zeppegno P, Krenkli M, Ferrante D, Bagnati M, Burgio V, Farruggio S, **Rolla R**, Gramaglia C, Grossini E. *Cancers (Basel)* 2021 Apr 7;13(8):1752. doi: 10.3390/cancers13081752
57. Circulating Exosomes Are Strongly Involved in SARS-CoV-2 Infection. Barberis E, Vanella VV, Falasca M, Caneapero V, Cappellano G, Raineri D, Ghirmoldi M, De Giorgis V, Puricelli C, Vaschetto R, Sainaghi PP, Bruno S, Sica A, Dianzani U, **Rolla R**, Chiocchetti A, Cantaluppi V, Baldanzi G, Marengo E, Manfredi M. *Front Mol Biosci*. 2021 Feb 22; 8: 632290. doi: 10.3389/fmolb.2021.632290. eCollection 2021. PMID: 33693030 Free PMC article.
58. Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Bellan M, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, Carriero A, Amico CS, Avanzi GC, Barini M, Battaglia M, Bor S, Cantaluppi V, Cappellano G, Ceruti F, Chiocchetti A, Clivati E, Giordano M, Cuneo D, Gambaro E, Gattoni E, Loro A, Manfredi M, Morosini U, Murano F, Paracchini E, Patti G, Pinato DJ, Raineri D, **Rolla R**, Sainaghi PP, Tricca S, Pirisi M. *Sci Rep*. 2021 Nov 22;11(1):22666. doi: 10.1038/s41598-021-01215-4. PMID: 34811387.
59. Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate. Barberis E, Amede E, Khoso S, Castello L, Sainaghi PP, Bellan M, Balbo PE, Patti G, Brustia D, Giordano M, **Rolla R**, Chiocchetti A, Romani G, Manfredi M, Vaschetto R. *Metabolites*. 2021 Dec 6;11(12):847. doi: 10.3390/metabo11120847. PMID: 34940605.
60. Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor Verdoia M, **Rolla R**, Pergolini P, Gioscia R, Nardin M, Negro F, Viglione F, Suryapranata H, Kedhi E, De Luca G; Novara Atherosclerosis Study Group (NAS).. *Catheter Cardiovasc Interv*. 2021 Dec 1;98(7):1309-1316. doi: 10.1002/ccd.29512. Epub 2021 Feb 1. PMID: 33527669.
61. Oral microbiota and vitamin D impact on oropharyngeal squamous cell carcinogenesis: a narrative literature review. Zanetta P, Squarzanti DF, Sorrentino R, **Rolla R**, Aluffi Valletti P, Garzaro M, Dell'Era V, Amoroso A, Azzimonti B. *Crit Rev Microbiol*. 2021 Mar;47(2):224-239. doi: 10.1080/1040841X.2021.1872487. Epub 2021 Jan 21. PMID: 33476522
62. Circulating Platelet-Derived Extracellular Vesicles Are a Hallmark of Sars-Cov-2 Infection. Cappellano G, Raineri D, **Rolla R**, Giordano M, Puricelli C, Vilardo B, Manfredi M, Cantaluppi V, Sainaghi PP, Castello L, De Vita N, Scotti L, Vaschetto R, Dianzani U, Chiocchetti A. *Cells*. 2021 Jan 7;10(1):85. doi: 10.3390/cells10010085. PMID: 33430260 Free PMC article.
63. An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient. Bruna R, Moia R, Valpreda A, Dosio E, **Rolla R**, Federici A, Dianzani U, Gaidano G, Patriarca A. *Clin Case Rep*. 2020 Dec 1;9(1):98-101. doi: 10.1002/ccr3.3452. eCollection 2021 Jan. PMID: 33489140 Free PMC article.
64. Short-Term Effects of Supplemental L-Arginine, Diosmin, Troxerutin, and Hesperidin in Diabetic Patients: A Pilot Study. Bagnati M, Puricelli C, Bauce G, Basile M, Grigollo B, Prodham F, Dianzani U, Bellomo G, **Rolla R**. *Biomed Res Int*. 2021 Dec 2;2021:3508281. doi: 10.1155/2021/3508281. eCollection 2021. PMID: 34901269.
65. Association of lower vitamin D levels with inflammation and leucocytes parameters in patients with and without diabetes mellitus undergoing coronary angiography. Verdoia M, Nardin M, **Rolla R**, Negro F, Gioscia R, Afifeh AMS, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). *Eur J Clin Invest*. 2021 Apr;51(4): e13439. doi: 10.1111/eci.13439. Epub 2020 Nov 20. PMID: 33112413
66. Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2. Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, Raineri D, Cittone MG, Rizzi E, Pedrinelli AR, Vassia V, Casciaro FG, Priora S, Nerici I, Galbiati A, Hayden E, Falasca M, Vaschetto R, Sainaghi PP,

- Dianzani U, **Rolla R**, Chiocchetti A, Baldanzi G, Marengo E, Manfredi M. *Int J Mol Sci*. 2020 Nov 16;21(22):8623. doi: 10.3390/ijms21228623. PMID: 33207699 Free PMC article.
67. Low vitamin D levels affect left ventricular wall thickness in severe aortic stenosis. Verdoia M, Solli M, Ubertini E, Erbetta R, Gioscia R, Afifeh AMS, Viglione F, **Rolla R**, De Luca G. *J Cardiovasc Med (Hagerstown)*. 2020 Nov;21(11):905-911. doi: 10.2459/JCM.0000000000001084. PMID: 32858630
 68. Cholecalciferol levels, inflammation and leukocytes parameters: Results from a large single-centre cohort of patients. Verdoia M, Nardin M, **Rolla R**, Negro F, Gioscia R, Saghir Afifeh AM, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). *Clin Nutr*. 2021 Apr;40(4):2228-2236. doi: 10.1016/j.clnu.2020.09.054. Epub 2020 Oct 19. PMID: 33121835.
 69. Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Suryapranata H, Kedhi E, De Luca G; Novara Atherosclerosis Study Group (NAS). *J Cardiovasc Med (Hagerstown)*. 2021 Sep 1;22(9):686-692. doi: 10.2459/JCM.0000000000001222. PMID: 34280175.
 70. Vitamin D deficiency is associated with impaired reperfusion in STEMI patients undergoing primary percutaneous coronary intervention. Verdoia M, Viglione F, Boggio A, Stefani D, Panarotto N, Malabaila A, **Rolla R**, Soldà PL, De Luca G; Novara Atherosclerosis Study Group (NAS). *Vascul Pharmacol*. 2021 Oct;140:106897. doi: 10.1016/j.vph.2021.106897. Epub 2021 Jul 16. PMID: 34274529.
 71. Screening for haemoglobin disorders: The experience of the piedmont north-eastern quadrant. **Rolla R**, Paglino G, Puricelli C, Mellone S, Sciancalepore M, Beltrami E, Cerutti C, Piccotti S, Tota S, Scotta A, Pergolini P, Dianzani U, Giordano M. *Int J Lab Hematol*. 2021 Apr;43(2): e61-e63. doi: 10.1111/ijlh.13364. Epub 2020 Oct 19. PMID: 33078543 No abstract available.
 72. Probiotics-addicted low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): A protocol of placebo-controlled randomized trial. De Mauri A, Carrera D, Bagnati M, **Rolla R**, Chiarinotti D, Mogna L, Pane M, Amoruso A, Del Piano M. *JOURNAL OF FUNCTIONAL FOODS* Volume: 74 ; Article Number: 104133 Published: NOV 2020
 73. Effects of Probiotics Administration on Human Metabolic Phenotype. Ghini V, Tenori L, Pane M, Amoruso A, Marroncini G, Squarzanti DF, Azzimonti B, **Rolla R**, Savoia P, Tarocchi M, Galli A, Luchinat C. *Metabolites*. 2020 Oct 7;10(10):396. doi: 10.3390/metabo10100396. PMID: 33036487 Free PMC article.
 74. Determinants of vitamin D activation in patients with acute coronary syndromes and its correlation with inflammatory markers. Saghir Afifeh AM, Verdoia M, Nardin M, Negro F, Viglione F, **Rolla R**, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis*. 2021 Jan 4;31(1):36-43. doi: 10.1016/j.numecd.2020.09.021. Epub 2020 Sep 24. PMID: 33308994 Free PMC article.
 75. Multicentric evaluation of analytical performances digital morphology with respect to the reference methods by manual optical microscopy. Da Rin G, Benegiamo A, Di Fabio AM, Dima F, Francione S, Fanelli A, Germagnoli L, Lorubbio M, Marzoni A, Pajola R, Pipitone S, **Rolla R**, Seghezzi M, Baigorria Vaca MDC, Bartolini A, Buoro S. *J Clin Pathol*. 2020 Sep 14; jclinpath-2020-206857. doi: 10.1136/jclinpath-2020-206857. Online ahead of print. PMID: 32928940
 76. Reduced activity of B lymphocytes, recognised by Sysmex XN-2000™ haematology analyser, predicts mortality in patients with coronavirus disease 2019. **Rolla R**, Vidali M, Puricelli C, Scotta AM, Pedrinelli A, Pergolini P, Pirisi M, Dianzani U, Rigamonti C. *Int J Lab Hematol*. 2021 Feb;43(1):e5-e8. doi: 10.1111/ijlh.13331. Epub 2020 Sep 7. PMID: 32893487 No abstract available.
 77. Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor. Verdoia M, Tonon F, Gioscia R, Nardin M, Fierro N, Sagazio E, Negro F, Pergolini P, **Rolla R**, De Luca G; Novara Atherosclerosis Study Group (NAS). *Thromb Res*. 2020 Dec; 196: 231-237. doi: 10.1016/j.thromres.2020.09.006. Epub 2020 Sep 3. PMID: 32916566
 78. Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASi) among patients undergoing percutaneous coronary intervention. Verdoia M, Nardin M, **Rolla R**, Negro F, Gioscia R, Saghir Afifeh AM, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). *Pharmacol Res*. 2020 Oct;160: 105158. doi: 10.1016/j.phrs.2020.105158. Epub 2020 Aug 22. PMID: 32841717
 79. Prognostic impact of Vitamin D deficiency in patients with coronary artery disease undergoing percutaneous coronary intervention. Verdoia M, Nardin M, **Rolla R**, Negro F, Gioscia R, Afifeh AMS, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). *Eur J Intern Med*. 2021 Jan; 83:62-67. doi: 10.1016/j.ejim.2020.08.016. Epub 2020 Aug 20. PMID: 32830035
 80. Multicenter evaluation of analytical performances of platelet counts and platelet parameters: Carryover, precision, and stability. Gioia M, Da Rin G, Manenti B, Birindelli S, Ciardelli ML, Gentile R, Beretta G, Lorusso G, Avino D, Di Fabio AM, Dima F, Fanelli A, Lorubbio M, Francione S, Marincheva G, Marini A, Papa A, Giannelli E,

- Pajola R, Panzeri A, Pipitone S, Benegiamo A, **Rolla R**, Vidali M, Buoro S. *Int J Lab Hematol*. 2020 Oct;42(5):552-564. doi: 10.1111/ijlh.13204. Epub 2020 Apr 18. PMID: 32304271
81. Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Negro F, Gioscia R, Fierro N, Saghir Afifeh AM, Viglione F, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Cardiovasc Revasc Med*. 2020 Sep;21(9):1144-1149. doi: 10.1016/j.carrev.2020.02.007. Epub 2020 Feb 13. PMID: 32085942
 82. Impact of diabetes mellitus on immature platelet fraction and its association with coronary artery disease. Verdoia M, Nardin M, **Rolla R**, Pergolini P, Suryapranata H, Kedhi E, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Diabetes Metab Res Rev*. 2020 May;36(4): e3290. doi: 10.1002/dmrr.3290. Epub 2020 Feb 5. PMID: 31943700
 83. Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. Moia R, Boggio E, Gigliotti L, Crisà E, De Paoli L, Margiotta Casaluci G, **Rolla R**, Patriarca A, Gaidano G, Dianzani U, Bruna R. *Hematol Oncol*. 2020 Apr;38(2):204-206. doi: 10.1002/hon.2700. Epub 2020 Jan 27. PMID: 31985842 No abstract available.
 84. Impact of aging on immature platelet count and its relationship with coronary artery disease. Verdoia M, Nardin M, Negro F, Tonon F, Gioscia R, **Rolla R**, De Luca G. *Platelets*. 2020 Nov 16;31(8):1060-1068. doi: 10.1080/09537104.2020.1714572. Epub 2020 Jan 23. PMID: 31973643
 85. Lipoprotein-associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects. De Mauri A, Vidali M, Chiarinotti D, Dianzani U, **Rolla R**. *Ther Apher Dial*. 2020 Oct;24(5):548-553. doi: 10.1111/1744-9987.13465. Epub 2020 Jan 21. PMID: 31863555
 86. Impact of active smoking on the immature platelet fraction and its relationship with the extent of coronary artery disease. Nardin M, Verdoia M, Negro F, **Rolla R**, Tonon F, De Luca G. *Eur J Clin Invest*. 2020 Feb;50(2): e13181. doi: 10.1111/eci.13181. Epub 2020 Jan 18. PMID: 31659742.
 87. A survey on the quality of the hematological reporting among the Italian laboratories. R. Pajola B. Manenti D. Giavarina D. Avino M.L. Ciardelli B. Cremonesi G. Da Rin A. Di Fabio F. Dima A. Fanelli S. Francione L. Germagnoli G. Introcaso M. Gioia A. Marini A. Papa S. Pipitone R. **Rolla R**. F. Tosato C. Ortolani S. Buoro. *Biochimica Clinica* 2020; 44(2) 129-142, DOI: 10.19186/BC_2019.061
 88. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Tonon F, Kedhi E, Suryapranata H, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *J Thromb Thrombolysis*. 2019 Oct;48(3):413-421. doi: 10.1007/s11239-019-01873-2. PMID: 31065927
 89. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor. Verdoia M, **Rolla R**, Negro F, Tonon F, Pergolini P, Nardin M, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis*. 2020 Feb 10;30(2):292-299. doi: 10.1016/j.numecd.2019.09.018. Epub 2019 Sep 30. PMID: 31780401
 90. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Negro F, Kedhi E, Suryapranata H, Marcolongo M, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Vascul Pharmacol*. 2019 Sep; 120:106564. doi: 10.1016/j.vph.2019.106564. Epub 2019 Jun 7. PMID: 31176855
 91. Impact of long-term therapy with acetylsalicylic acid on immature platelet count: a single-centre cohort study. Verdoia M, Nardin M, Negro F, **Rolla R**, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *J Cardiovasc Med (Hagerstown)*. 2019 May;20(5):306-312. doi: 10.2459/JCM.0000000000000786. PMID: 30865138
 92. Outcomes of music therapy interventions in cancer patients-A review of the literature. Gramaglia C, Gambaro E, Vecchi C, Licandro D, Raina G, Pisani C, Burgio V, Farruggio S, **Rolla R**, Deantonio L, Grossini E, Krengli M, Zeppego P. *Crit Rev Oncol Hematol*. 2019 Jun;138: 241-254. doi: 10.1016/j.critrevonc.2019.04.004. Epub 2019 Apr 5. PMID: 31121392 Review.
 93. Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. Sciascia S, Radin M, Cecchi I, Rubini E, Scotta A, **Rolla R**, Montaruli B, Pergolini P, Mengozzi G, Muccini E, Baldovino S, Ferro M, Vaccarino A, Mahler M, Menegatti E, Roccatello D. *Front Immunol*. 2019 Mar 5; 10:376. doi: 10.3389/fimmu.2019.00376. eCollection 2019. PMID: 30891041 Free PMC article.
 94. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Barbieri L, Marino P, Carriero A, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. *J Cardiol*. 2019 Mar;73(3):198-203. doi: 10.1016/j.jjcc.2018.10.005. Epub 2018 Dec 3. PMID: 30522897 Free article.

95. Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy. Verdoia M, Pergolini P, **Rolla R**, Ceccon C, Caputo M, Aimaretti G, Suryapranata H, De Luca G. *Exp Clin Endocrinol Diabetes*. 2021 Jan;129(1):43-49. doi: 10.1055/a-0787-1382. Epub 2018 Nov 29. PMID: 30497083
96. Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. Verdoia M, Pergolini P, **Rolla R**, Suryapranata H, Kedhi E, De Luca G on behalf of the Novara Atherosclerosis Study Group (NAS). *Platelets*. 2019;30(7):915-922. doi: 10.1080/09537104.2018.1535707. Epub 2018 Nov 13. PMID: 30422043
97. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients. De Mauri A, Vidali M, Chiarinotti D, Bellomo G, **Rolla R**. *J Nephrol*. 2019 Apr;32(2):283-288. doi: 10.1007/s40620-018-0521-3. Epub 2018 Aug 27. PMID: 30168082
98. The diagnosis of malaria: the role of the haematology analyzers as first level screening. **Rolla R**, Da Rin G, Granero V et al. Group Author(s): Nome Grp Diagnostica Ematologica. *BIOCHIMICA CLINICA* Volume: 42 Issue: 3 Pages: 191-209 Published: SEP 2018
99. Impact of statin therapy on the immature platelet count in patients with coronary artery disease: A single centre cohort study. Verdoia M, Nardin M, Negro F, **Rolla R**, De Luca G; Novara Atherosclerosis Study Group (NAS). *Int J Cardiol*. 2018 Dec 1; 272: 40-44. doi: 10.1016/j.ijcard.2018.08.039. Epub 2018 Aug 11. PMID: 30150123
100. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. Verdoia M, Pergolini P, Barbieri L, **Rolla R**, Nardin M, Negro F, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Thromb Res*. 2018 Apr; 164: 17-23. doi: 10.1016/j.thromres.2018.02.008. Epub 2018 Feb 15. PMID: 29475177
101. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Nardin M, Verdoia M, Pergolini P, **Rolla R**, Barbieri L, Marino P, Bellomo G, Kedhi E, Suryapranata H, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Pharmacol Res*. 2018 Mar; 129: 27-33. doi: 10.1016/j.phrs.2017.12.035. Epub 2018 Jan 31. PMID: 29355684
102. Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity. Verdoia M, Pergolini P, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Angiology*. 2018 Jul;69(6):490-496. doi: 10.1177/0003319717736407. Epub 2017 Oct 29. PMID: 29082748
103. Impact of polymorphism rs7041 and rs4588 of Vitamin D Binding Protein on the extent of coronary artery disease. Daffara V, Verdoia M, **Rolla R**, Nardin M, Marino P, Bellomo G, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis*. 2017 Sep;27(9):775-783. doi: 10.1016/j.numecd.2017.06.002. Epub 2017 Jun 24. PMID: 28779988
104. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M, Daffara V, Pergolini P, **Rolla R**, Marino P, Bellomo G, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). *Vascul Pharmacol*. 2017 Aug;93-95:42-47. doi: 10.1016/j.vph.2017.04.001. Epub 2017 Apr 19. PMID: 28433569
105. Immature platelet fraction and the extent of coronary artery disease: A single centre study. Verdoia M, Nardin M, **Rolla R**, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Atherosclerosis*. 2017 May; 260:110-115. doi: 10.1016/j.atherosclerosis.2017.03.044. Epub 2017 Mar 31. PMID: 28388444
106. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Verdoia M, Pergolini P, **Rolla R**, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Thromb Res*. 2017 Feb; 150:90-95. doi: 10.1016/j.thromres.2016.12.019. Epub 2016 Dec 28. PMID: 28068529
107. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel or Ticagrelor. Verdoia M, Pergolini P, **Rolla R**, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Cardiovasc Ther*. 2016 Aug;34(4):209-15. doi: 10.1111/1755-5922.12188. PMID: 27086085 Free article.
108. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. Verdoia M, Pergolini P, Nardin M, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. *J Thromb Thrombolysis*. 2016 Aug;42(2):245-53. doi: 10.1007/s11239-016-1348-1. PMID: 26951167
109. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. Verdoia M, Sartori C, Pergolini P, Nardin M, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. *J Thromb Thrombolysis*. 2016 May;41(4):663-70. doi: 10.1007/s11239-015-1279-2. PMID: 26370198 Clinical Trial.

110. Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. Nardin M, Verdoia M, Sartori C, Pergolini P, **Rolla R**, Barbieri L, Schaffer A, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Thromb Res.* 2016 Jul; 143: 45-9. doi: 10.1016/j.thromres.2016.04.021. Epub 2016 Apr 27. PMID: 27179132 No abstract available.
111. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M, Pergolini P, **Rolla R**, Sartori C, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Platelets.* 2016 Sep;27(6):576-82. doi: 10.3109/09537104.2016.1149159. Epub 2016 Apr 11. PMID: 27540959
112. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. Verdoia M, Pergolini P, **Rolla R**, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, Luca GD; Novara Atherosclerosis Study Group (NAS). *Cardiovasc Drugs Ther.* 2016 Apr;30(2):143-50. doi: 10.1007/s10557-016-6646-5. PMID: 26868495
113. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nardin M, Verdoia M, Pergolini P, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis.* 2016 Jul;26(7):567-574. doi: 10.1016/j.numecd.2016.03.001. Epub 2016 Mar 15. PMID: 27134063
114. Below normal pre-procedural cardiac troponin I levels are associated with an adverse prognosis after percutaneous coronary interventions. Lupi A, Rognoni A, Lazzeri M, **Rolla R**, Pergolini P, Bellomo G, Rossi L, Sante Bongo A, Jaffe AS. *EuroIntervention.* 2016 Mar;11(12):1380-8. doi: 10.4244/EIJY14M11_04. PMID: 25405803 Free article.
115. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Barbieri L, Verdoia M, Pergolini P, Nardin M, **Rolla R**, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Nutr Metab Cardiovasc Dis.* 2016 Apr;26(4):352-8. doi: 10.1016/j.numecd.2015.12.015. Epub 2016 Jan 6. PMID: 26857781
116. Polymorphisms Associated with Increased Cardiovascular Risk in the General Population do not Predict Acute Events in Hemodialysis Patients. **Rolla R**, De Mauri A, Vidali M, Valsesia A, Chiarinotti D, Bellomo G. *Clin Lab.* 2016;62(4):639-44. doi: 10.7754/clin.lab.2015.150813. PMID: 27215083
117. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M, Pergolini P, **Rolla R**, Nardin M, Schaffer A, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G. *J Thromb Haemost.* 2016 Jan;14(1):57-64. doi: 10.1111/jth.13177. Epub 2015 Dec 29. PMID: 26512550 Free article.
118. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Barbieri L, Pergolini P, Verdoia M, **Rolla R**, Nardin M, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Vascul Pharmacol.* 2016 Apr ;79: 11-15. doi: 10.1016/j.vph.2015.10.006. Epub 2015 Oct 28. PMID: 26518440
119. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Verdoia M, Nardin M, Sartori C, Pergolini P, **Rolla R**, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Atherosclerosis.* 2015 Dec;243(2):389-94. doi: 10.1016/j.atherosclerosis.2015.10.005. Epub 2015 Oct 9. PMID: 26520891
120. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. Nardin M, Verdoia M, Sartori C, Pergolini P, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. *J Cardiovasc Pharmacol.* 2015 Oct;66(4):364-70. doi: 10.1097/FJC.000000000000288. PMID: 26065844
121. Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated with Acetylsalicylic Acid. Verdoia M, Schaffer A, Pergolini P, **Rolla R**, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *J Cardiovasc Pharmacol.* 2015 Jul;66(1):35-40. doi: 10.1097/FJC.000000000000240. PMID: 25714593
122. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients. **Rolla R**, De Mauri A, Valsesia A, Vidali M, Chiarinotti D, Bellomo G. *J Nephrol.* 2015 Dec;28(6):749-55. doi: 10.1007/s40620-015-0194-0. Epub 2015 May 14. PMID: 25971848
123. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Verdoia M, Sartori C, Pergolini P, Nardin M, **Rolla R**, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Vascul Pharmacol.* 2016 Feb;77: 48-53. doi: 10.1016/j.vph.2015.04.014. Epub 2015 May 6. PMID: 25956733
124. Similar anti-inflammatory effects of intracoronary and intravenous abciximab during primary percutaneous coronary intervention: a randomized study. Secco GG, Sansa M, Rognoni A, Parisi R, Fattori R, Rossi L, Lazzeri M, **Rolla R**, Bellomo G, Bongo AS, Agostoni P, Di Mario C, Lupi A. *J Cardiovasc Med (Hagerstown).* 2015 Mar;16(3):189-96. doi: 10.2459/JCM.000000000000119. PMID: 25022932 Clinical Trial.

125. Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. Verdoia M, Pergolini P, **Rolla R**, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Cardiovasc Drugs Ther.* 2015;29(5):443-50. doi: 10.1007/s10557-015-6616-3. PMID: 26428927
126. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G. *Expert Opin Pharmacother.* 2015;16(12):1739-47. doi: 10.1517/14656566.2015.1056151. Epub 2015 Jun 12. PMID: 26067422
127. Neonatal screening for sickle cell disease and other hemoglobinopathies in "the changing Europe". **Rolla R**, Castagno M, Zaffaroni M, Grigollo B, Colombo S, Piccotti S, Dellora C, Bona G, Bellomo G. *Clin Lab.* 2014;60(12):2089-93. doi: 10.7754/clin.lab.2014.140701. PMID: 25651745
128. Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism. **Rolla R**, Pergolini P, Vidali M, Pollarolo P, Appiani A, Cerutti C, Manzini M, Crisci A, Bellomo G. *Clin Lab.* 2014;60(10):1725-33. doi: 10.7754/clin.lab.2014.140215. PMID: 25651720
129. Does asymmetric dimethylarginine (ADMA) plasma concentration predict esophageal varices in patients with cirrhosis? **Rolla R**, Vidali M, Sartori M, Andorno S, Pagliarulo M, Carmagnola S, Ballaré M, Orsello M, Montino F, Anderloni A, Suno A, Del Piano M, Bellomo G. *Clin Lab.* 2014;60(5):791-8. doi: 10.7754/clin.lab.2013.130534. PMID: 24839822
130. An observational study of Venlafaxine and CYP2D6 in clinical practice. **Rolla R**, Gramaglia C, Dalò V, Ressico F, Prosperini P, Vidali M, Meola S, Pollarolo P, Bellomo G, Torre E, Zeppego P. *Clin Lab.* 2014;60(2):225-31. doi: 10.7754/clin.lab.2013.130141. PMID: 24660534
131. PIA(1)/PIA(2) polymorphism does not influence response to Gp IIb/IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M, Pergolini P, Camaro C, Restifo M, **Rolla R**, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). *Blood Coagul Fibrinolysis.* 2013 Jun;24(4):411-8. doi: 10.1097/MBC.0b013e32835d546e. PMID: 23412353
132. Combined and sequential use of activated protein C resistance and molecular genetic test for the diagnosis of factor V Leiden: a new laboratory approach. **Rolla R**, Bellomo G. *Clin Lab.* 2013;59(9-10):1187-8. doi: 10.7754/clin.lab.2013.130148. PMID: 24273947 No abstract available.
133. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Vidali M, **Rolla R**, Parrella M, Cassani C, Manzini M, Portalupi MR, Serino R, Prando MD, Bellomo G, Pergolini P. *Int J Lab Hematol.* 2012 Oct;34(5):484-94. doi: 10.1111/j.1751-553X.2012.01428.x. Epub 2012 May 21. PMID: 22613071
134. Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention. Lupi A, Secco GG, Rognoni A, Rossi L, Lazzeri M, Nardi F, **Rolla R**, Bellomo G, Bongo AS, Di Mario C. *J Thromb Thrombolysis.* 2012 May;33(4):308-17. doi: 10.1007/s11239-011-0628-z. PMID: 21909639
135. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early-stage breast cancer treated with tamoxifen. **Rolla R**, Vidali M, Meola S, Pollarolo P, Fanello MR, Nicolotti C, Saggia C, Forti L, Agostino FD, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G. *Clin Lab.* 2012;58(11-12):1211-8. PMID: 23289191
136. Hemolysis is a major cause of variability in insulin measurement during oral glucose tolerance test in children. Bellomo G, Sulas MG, Mairate E, Bardone MB, **Rolla R**. *Clin Lab.* 2012;58(1-2):67-74. PMID: 22372347
137. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden. **Rolla R**, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G. *Clin Lab.* 2011;57(9-10):711-7. PMID: 22029186
138. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. **Rolla R**, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. *Clin Exp Immunol.* 2007 Jul;149(1):63-9. doi: 10.1111/j.1365-2249.2007.03404.x. Epub 2007 May 4. PMID: 17488295 Free PMC article.
139. Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C. Sartori M, Andorno S, Pagliarulo M, Rigamonti C, Bozzola C, Pergolini P, **Rolla R**, Suno A, Boldorini R, Bellomo G, Albano E. *Gut.* 2007 May;56(5):693-8. doi: 10.1136/gut.2006.106641. Epub 2006 Nov 29. PMID: 17135308 Free PMC article.
140. Use of molecular simulation for mapping conformational CYP2E1 epitopes. Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, **Rolla R**, Occhino G, Albano E, Ingelman-Sundberg M. *J Biol Chem.* 2004 Dec 3;279(49):50949-55. doi: 10.1074/jbc.M407329200. Epub 2004 Sep 28. PMID: 15456790 Free article.
141. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Rigamonti C, Mottaran E, Reale E, **Rolla R**, Cipriani V, Capelli F, Boldorini R, Vidali M, Sartori M, Albano E. *Hepatology.* 2003 Jul;38(1):42-9. doi: 10.1053/jhep.2003.50275. PMID: 12829985

142. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Vidali M, Stewart SF, **Rolla R**, Daly AK, Chen Y, Mottaran E, Jones DE, Leathart JB, Day CP, Albano E. *Hepatology*. 2003 Feb;37(2):410-9. doi: 10.1053/jhep.2003.50049. PMID: 12540792
143. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Stewart SF, Leathart JB, Chen Y, Daly AK, **Rolla R**, Vay D, Mottaran E, Vidali M, Albano E, Day CP. *Hepatology*. 2002 Dec;36(6):1355-60. doi: 10.1053/jhep.2002.36940. PMID: 12447859
144. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Mottaran E, Stewart SF, **Rolla R**, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. *Free Radic Biol Med*. 2002 Jan 1;32(1):38-45. doi: 10.1016/s0891-5849(01)00757-2. PMID: 11755315
145. Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. **Rolla R**, Vay D, Mottaran E, Parodi M, Vidali M, Sartori M, Rigamonti C, Bellomo G, Albano E. *Gut*. 2001 Dec;49(6):852-9. doi: 10.1136/gut.49.6.852. PMID: 11709522 Free PMC article.
146. Circulating antibodies recognizing malondialdehyde-modified proteins in healthy subjects. Vay D, Parodi M, **Rolla R**, Mottaran E, Vidali M, Bellomo G, Albano E. *Free Radic Biol Med*. 2001 Feb 1;30(3):277-86. doi: 10.1016/s0891-5849(00)00469-x. PMID: 11165874
147. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Vay D, Vidali M, Allochis G, Cusaro C, **Rolla R**, Mottaran E, Bellomo G, Albano E. *Diabetologia*. 2000 Nov;43(11):1385-8. doi: 10.1007/s001250051543. PMID: 11126407
148. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. **Rolla R**, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, Bellomo G, Klassen LW, Thiele GM, Tuma DJ, Albano E. *Hepatology*. 2000 Apr;31(4):878-84. doi: 10.1053/he.2000.5373. PMID: 10733543.

ATTI IN CONGRESSI INTERNAZIONALI PUBBLICATI SU RIVISTA

149. A Ghisletti, C Puricelli, A Giordano, G Maulini, S Sacchetti, L Giacomini, G Mazzola, M Basile, M Bagnati, **R Rolla**, D D'amario, G Patti, PROCARDIO study: from gut to heart, a new path to vascular protection, *European Heart Journal*, Volume 46, Issue Supplement_1, November 2025, ehaf784.3858, <https://doi.org/10.1093/eurheartj/ehaf784.3858>
150. S. Sacchetti, M. Bellia, M. Vidali, L. Giacomini, V. Zanotti, A. Patriarca, U. Dianzani, G. Gaidano, **R. Rolla**. Exploring artificial intelligence techniques for morphological analysis of digital images of peripheral blood cells: MC-80 versus HemaVision. *Clinica Chimica Acta*, Volume 558, Supplement 1, 2024, 118809, ISSN 0009-8981, <https://doi.org/10.1016/j.cca.2024.118809> (<https://www.sciencedirect.com/science/article/pii/S0009898124010507>)
151. P.A. Tillio, A. Mora, A. Conca, U. Dianzani, **R. Rolla**. Evaluation of the reliability of the Friedewald equation in the measurement of LDL values. *Clinica Chimica Acta*, Volume 558, Supplement 1, 2024, 118018, ISSN 0009-8981, <https://doi.org/10.1016/j.cca.2024.118018> (<https://www.sciencedirect.com/science/article/pii/S0009898124002596>)
152. S. Sacchetti, V. Zanotti, L. Giacomini, M. Sciancalepore, S. Tota, S. Piccotti, U. Dianzani, **R. Rolla**. Malaria infection reveals hemoglobinopathy: A pediatric sickle cell anemia case reports. *Clinica Chimica Acta*, Volume 558, Supplement 1, 2024, 118345, ISSN 0009-8981, <https://doi.org/10.1016/j.cca.2024.118345> (<https://www.sciencedirect.com/science/article/pii/S0009898124005862>)
153. Platelet function and autonomic nervous system dysregulation in newly diagnosed hypertensive condition. Grossini E, De Zanet D, Migliavacca S, Pirisi M, **Rolla R** et al. *ACTA PHYSIOLOGICA* Volume: 227 Special Issue: SI Supplement: 718 Pages: 170-171 Meeting Abstract: PP.260 Published: SEP 2019.
154. Prognostic role of vitamin d deficiency in stemi patients undergoing primary percutaneous coronary intervention. Verdoia M, Gioscia R, **Rolla R**, Rognoni A, De Luca G. *EUROPEAN HEART JOURNAL SUPPLEMENTS* Meeting Abstract: 265 Volume: 24 Article Number: suac121.336 DOI: 10.1093/eurheartjsupp/suac121.336 Published Date: 2022 DEC Supplement: K.
155. LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PREDICTS THE LOWER LIMB ISCHEMIA IN DIALYZED PATIENTS. De Mauri A, Vidali M, **Rolla R** et al. Conference: 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease. Budapest, HUNGARY Date: JUN 13-16, 2019. *NEPHROLOGY DIALYSIS TRANSPLANTATION* Volume: 34 Supplement: 1 Pages: 261-261 Meeting Abstract: FP636 Published: JUN 2019.
156. MEDITERRANEAN ADEQUACY INDEX AMONG PATIENTS WITH ADVANCED RENAL FAILURE. De Mauri A, Carrera D, **Rolla R** et al. Conference: 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease. Budapest, HUNGARY Date:

- JUN 13-16, 2019. NEPHROLOGY DIALYSIS TRANSPLANTATION Volume: 34 Supplement: 1 Pages: 494 -U746 Meeting Abstract: SP403 Published: JUN 2019.
157. LOW PROTEIN DIET REDUCES MICROBIAL AND INFLAMMATORY TOXINS IN ADVANCED RENAL FAILURE. De Mauri A, Vidali M, **Rolla R** et al. Conference: 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease. Budapest, HUNGARY Date: JUN 13-16, 2019. NEPHROLOGY DIALYSIS TRANSPLANTATION Volume: 34 Supplement: 1 Meeting Abstract: SP383 Published: JUN 2019.
 158. POLYMORPHISM RS2762939 OF CYP24A1 ENZYME AND CORONARY ARTERY DISEASE: ANGIOGRAPHIC RESULTS FROM A LARGE PROSPECTIVE COHORT OF PATIENTS. Verdoia M, **Rolla R**, Nardin M et al. Conference: 68th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) Location: New Orleans, LA Date: MAR 16-18, 2019. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Volume: 73 Issue: 9 Supplement: 1 Pages: 49-49 Meeting Abstract: 1130-372 Published: MAR 12 2019.
 159. Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. Radin M, Cecchi I, Rubini E, Scotta A, **Rolla R** et al. ARTHRITIS & RHEUMATOLOGY Volume: 70 Supplement: 9 Meeting Abstract: 164 Published: SEP 2018.
 160. IMPACT OF ADENOSINE A2A RECEPTOR POLYMORPHISM RS5751876 ON PLATELET REACTIVITY IN TICAGRELOR TREATED PATIENTS. Verdoia M, Nardin M, Barbieri L, **Rolla R** et al. Conference: 67th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) Location: Orlando, FL Date: MAR 10-12, 2018. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Volume: 71 Issue: 11 Supplement: S Pages: 99-99 Meeting Abstract: A99 Published: MAR 10 2018.
 161. Lp-PLA2 IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS IN DIALYZED PATIENTS. De Mauri A, Vidali M, Rolla R et al. NEPHROLOGY DIALYSIS TRANSPLANTATION Volume: 32 Supplement: 3 Pages: 706-706 Meeting Abstract: MP742 Published: MAY 2017.
 162. ASSOCIATION BETWEEN ULTRARAPID CYP2D6 POLYMORPHISMS AND ADVERSE DRUG REACTIONS AMONG WOMEN WITH BREAST CANCER TREATED WITH TAMOXIFEN. **Rolla R**, Vidali M, Meola S et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Supplement: 1 Pages: S668-S668 Published: MAY 2011.
 163. HEMOLYSIS IS A MAJOR CAUSE OF VARIABILITY IN INSULIN MEASUREMENT DURING ORAL GLUCOSE TOLERANCE TEST IN CHILDREN. **Rolla R**, Sulas MG, Bardone MB et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Supplement: 1 Pages: S644-S644 Published: MAY 2011.
 164. ROLE OF THE LABORATORY IN MONITORING PATIENTS RECEIVING DOUBLE ANTIPLATELET THERAPY. Vidali M, Pergolini P, **Rolla R** et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Supplement: 1 Pages: S514-S514 Published: MAY 2011.
 165. VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE: AN OBSERVATIONAL STUDY. Zeppego P, **Rolla R**, Dalo' V et al. EUROPEAN PSYCHIATRY Volume: 26 Supplement: 1 Meeting Abstract: P02-455 Published: 2011.
 166. VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE: WORK IN PROGRESS. Zeppego P, **Rolla R**, Dalo V et al. EUROPEAN PSYCHIATRY Volume: 25 Supplement: 1 Published: 2010.
 167. IS ASYMMETRIC DIMETHYLARGININE (ADMA) PLASMA LEVEL A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS WITH CIRRHOSIS? Sartori M, Andorno S, **Rolla R** et al. DIGESTIVE AND LIVER DISEASE Volume: 40 Supplement: 1 Pages: S102-S102 Meeting Abstract: PA.75 Published: MAR 2008
 168. Role of antibodies recognizing oxidized phospholipids in laboratory tests exploring lupus anticoagulant activity. **Rolla R**, Vidali M, Serino R et al. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Volume: 25 Issue: 2 Pages: 164-164 Published: MAR-APR 2007.
 169. Heterozygous beta globin gene mutations are associated with more severe liver fibrosis in patients with chronic hepatitis C. Sartori M, Andorno S, Rigamonti C, Capelli F, Bozzola C, Pergolini P, **Rolla R** et al. Conference: 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). Boston, MA Date: OCT 29-NOV 02, 2004. HEPATOLOGY Volume: 40 Issue: 4 Supplement: 1 Pages: 684 A-685A Published: OCT 2004.
 170. Characterisation of anti-CYP2E1 auto-antibodies associated with halothane hepatitis and alcoholic liver disease. Vidali M, Hidestrand M, Mottaran E, Reale E, **Rolla R** et al. Conference: 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver. Berlin, GERMANY Date: APR 14-18, 2004. JOURNAL OF HEPATOLOGY Volume: 40 Supplement: 1 Pages: 163-163 Meeting Abstract: 555 Published: APR 2004.
 171. Alcohol intake worsens oxidative stress and piecemeal necrosis in patients with chronic hepatitis. Rigamonti C, Mottaran E, Reale E, Capelli F, Maduli E, **Rolla R** et al. Conference: 38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver Location: ISTANBUL, TURKEY Date: MAR 29-APR 01, 2003. JOURNAL OF HEPATOLOGY Volume: 38 Supplement: 2 Pages: 165-165 Meeting Abstract: 568 Published: APR 2003.
 172. Moderate alcohol intake increases oxidative stress in patients with chronic hepatitis C. Sartori M, Maggiore O, Mottaran, Rigamonti C, Elisabetta M, Capelli F, **Rolla R** et al. Conference: 53rd Annual Meeting of the

- Association-for-the-Study-of-Liver-Diseases (AASLD). BOSTON, MASSACHUSETTS Date: NOV 01-05, 2002. HEPATOLOGY Volume: 36 Issue: 4 Supplement: S Pages: 385 A-385A Part: 2 Meeting Abstract: 889 Published: OCT 2002.
173. Role of CTLA-4 genetic polymorphism in the development of anti-cytochrome P4502E1 auto-antibodies during alcoholic liver disease. Vidali M, Stewart SF, **Rolla R** et al. HEPATOLOGY Volume: 34 Issue: 4 Supplement: S Pages: 251 A-251A Part: 2 Meeting Abstract: 312 Published: OCT 2001.
 174. Chronic hepatitis C and alcohol-induced oxidative stress. Morelli S, Rigamonti C, Maduli E, Andorno S, **Rolla R** et al. JOURNAL OF HEPATOLOGY Volume: 34 Supplement: 1 Pages: 199-200 Published: APR 2001.
 175. A polymorphism in CTLA-4 is associated with the presence of anti-CYP2E1 antibody titres in patients with alcoholic liver disease. Stewart SF, Daly AK, Chen Y, Leathart JB, Jones DEJ, **Rolla R** et al. JOURNAL OF HEPATOLOGY Volume: 34 Supplement: 1 Pages: 200-200 Published: APR 2001.
 176. Prevalence of auto-antibodies against cytochrome in alcoholic liver disease. Vidali M, **Rolla R**, Stewart SF et al. JOURNAL OF HEPATOLOGY Volume: 34 Supplement: 1 Pages: 195-195 Published: APR 2001.
 177. Alcohol-induced oxidative stress contributes to development of immune reactions associated with alcoholic liver disease. **Rolla R**, Stewart SF, Mottaran E et al. HEPATOLOGY Volume: 32 Issue: 4 Pages: 423 A-423A Part: 2 Meeting Abstract: 1054 Published: OCT 2000.
 178. Susceptibility to alcoholic liver disease is due to genetically determined differences in the immune response to acetaldehyde adducts. Stewart SF, Daly AK, Chen YN, Leathart JB, **Rolla R** et al. HEPATOLOGY Volume: 32 Issue: 4 Pages: 386 A-386A Part: 2 Meeting Abstract: 906 Published: OCT 2000.
 179. Oxidized phospholipids are the target of anti-phospholipid antibodies associated with alcoholic liver disease. Mottaran E, **Rolla R**, Vay D et al. HEPATOLOGY Volume: 30 Issue: 4 Supplement: S Pages: 435 A-435A Part: 2 Meeting Abstract: 1100 Published: OCT 1999.
 180. Alcohol-induced oxidative stress in patients with chronic hepatitis C. Sartori M, **Rolla R**, Mottaran E et al. HEPATOLOGY Volume: 32 Issue: 4 Pages: 496 A-496A Part: 2 Meeting Abstract: 1348 Published: OCT 2000.
 181. Malondialdehyde-acetaldehyde (MAA) adducts trigger immune reactions in patients with alcoholic liver disease. **Rolla R**, Vay D, Mottaran E et al. HEPATOLOGY Volume: 30 Issue: 4 Supplement: S Pages: 399 A-399A Part: 2 Meeting Abstract: 956 Published: OCT 1999.

Novara, 16 giugno 2026.